Biohaven’s attempts to redefine itself as a post-migraine company are continuing to encounter headaches, with the company expressing “deep disappointment” at the FDA’s refusal to review the brain disorder drug troriluzole.
Alzheimer's drug research notched yet another setback Monday, as a late-stage clinical trial found that an experimental medicine from Biohaven Pharmaceuticals did not significantly impact brain function in patients with mild to moderate disease.
LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
Biohaven Pharmaceutical Holding Company Ltd reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD).
Four months after Biohaven $BHVN reported that troriluzole flopped in a study for anxiety, the biotech is back with another setback to report. The therapy has now also failed at treating obsessive-compulsive disorder, though the execs in charge still see plenty of good reasons for forging ahead into a pivotal trial.
NEW HAVEN, Conn., June 24, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD).
Hereditary spinocerebellar ataxias (SCAs) are progressive neurodegenerative disorders that are characterized clinically by progressive ataxia and are attributed to various autosomal dominant genetic mutations. Currently, there is no US Food and Drug Administration (FDA)-approved medication for this debilitating disorder and, so, treatment remains supportive. This study compared patients in Study BHV4157-201 treated with troriluzole with patients selected from a natural history cohort of patients with SCA who were matched on multiple eligibility criteria. The objective was to provide a preliminary assessment of the long-term benefit of treatment with troriluzole (also known as BHV-4157) among patients with SCA.
Shares of Biohaven Pharmaceutical Holding Company Ltd fell 16% on Monday after its treatment for anxiety disorder failed to meet the main goal in a late-stage study.